CAS 928672-86-0|Canagliflozin hemihydrate

Introduction：Basic information about CAS 928672-86-0|Canagliflozin hemihydrate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Canagliflozin hemihydrate BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Canagliflozin hemihydrate
CAS Number	928672-86-0	Molecular Weight	453.52
Density	/	Boiling Point	/
Molecular Formula	C₂₄H₂₆FO_5.5S	Melting Point	/
MSDS	/	Flash Point	/

Names

Name	Canagliflozin hemihydrate
Synonym	More Synonyms

Canagliflozin hemihydrate BiologicalActivity

Description	Canagliflozin 0.5 H2O(JNJ 28431754; TA 7284) is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM, exhibits 413-fold selectivity over hSGLT1.IC50 value: 2.2 nMTarget: SGLT2Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
Related Catalog	Signaling Pathways >>Membrane Transporter/Ion Channel >>SGLTResearch Areas >>Metabolic Disease
References	[1]. Sumihiro Nomura et al. Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus J. Med. Chem., 2010, 53 (17), pp 6355-6360 [2]. Nicolle LE, Capuano G, Ways K, Usiskin K.Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.Curr Med Res Opin. 2012 Jul;28(7):1167-71. [3]. Rosenstock J, et al. Canagliflozin DIA 2001 Study Group.Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.Diabetes Care. 2012 Jun;35(6):1232-8. [4]. Liang Y, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.PLoS One. 2012;7(2):e30555. [5]. Devineni D, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.Diabetes Obes Metab. 2012 Jun;14(6):539-45. doi: 10.1111/j.1463-1326.2012.01558.x.

Description

Canagliflozin 0.5 H2O(JNJ 28431754; TA 7284) is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM, exhibits 413-fold selectivity over hSGLT1.IC50 value: 2.2 nMTarget: SGLT2Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.

Related Catalog

Signaling Pathways >>Membrane Transporter/Ion Channel >>SGLTResearch Areas >>Metabolic Disease

References

[1]. Sumihiro Nomura et al. Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus J. Med. Chem., 2010, 53 (17), pp 6355-6360

[2]. Nicolle LE, Capuano G, Ways K, Usiskin K.Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.Curr Med Res Opin. 2012 Jul;28(7):1167-71.

[3]. Rosenstock J, et al. Canagliflozin DIA 2001 Study Group.Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.Diabetes Care. 2012 Jun;35(6):1232-8.

[4]. Liang Y, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.PLoS One. 2012;7(2):e30555.

[5]. Devineni D, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.Diabetes Obes Metab. 2012 Jun;14(6):539-45. doi: 10.1111/j.1463-1326.2012.01558.x.

Chemical & Physical Properties

Molecular Formula	C₂₄H₂₆FO_5.5S
Molecular Weight	453.52
PSA	246.01000
LogP	5.87230
InChIKey	VHOFTEAWFCUTOS-TUGBYPPCSA-N
SMILES	Cc1ccc(C2OC(CO)C(O)C(O)C2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc(C2OC(CO)C(O)C(O)C2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O
Storage condition	-20℃

Synonyms

(1S)-1,5-Anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol hydrate (2:1)

(2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol,hydrate

UNII-0SAC974Z85

canagliflozin hydrate

D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-, hydrate (2:1)

Invokana

TA-7284

Canagliflozin (hemihydrate)

Recommended......